Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is an immune-mediated neuropathy characterized by progressive or relapsing weakness and sensory loss due to demyelination of peripheral nerves. Early diagnosis and treatment can prevent irreversible axonal damage and disability.
Symptoms
- Symmetric weakness in arms and legs (proximal and distal)
- Numbness, tingling, loss of vibration/proprioception
- Reduced reflexes or areflexia
- Gait instability, frequent falls
- Tremor, fatigue, neuropathic pain
- Cranial nerve or autonomic involvement in variants
Diagnosis
- History of symptom progression ≥ 8 weeks (distinguishes from Guillain-Barré)
- Neurologic exam with symmetric weakness and sensory deficits
- Nerve conduction studies/EMG showing demyelinating features (slowed conduction, conduction block, temporal dispersion)
- CSF analysis: elevated protein with normal cell count (albuminocytologic dissociation)
- MRI nerve root enhancement, nerve ultrasound (thickening)
- Exclude mimics: hereditary neuropathies, diabetes, toxins, amyloidosis
Treatment & Management
First-Line Immunotherapies
- Intravenous immunoglobulin (IVIG) loading + maintenance
- Corticosteroids (oral prednisone, pulsed IV methylprednisolone)
- Plasma exchange (PLEX) for acute worsening or IVIG-resistant cases
Steroid-Sparing/Second-Line
- Immunosuppressants: azathioprine, mycophenolate, cyclosporine, tacrolimus, methotrexate
- Cyclophosphamide or rituximab for refractory disease (especially autoimmune nodopathies)
- SCIG (subcutaneous immunoglobulin) for long-term maintenance and autonomy
Rehabilitation & Support
- Physical and occupational therapy for strength, balance, ADLs
- Orthotics/bracing for foot drop, mobility aids
- Pain management with gabapentinoids, SNRIs, TCAs
- Monitor for depression/anxiety; chronic disability impacts mental health
Monitoring
- Regular neurologic exams, strength testing, disability scales (INCAT, R-ODS)
- Nerve conduction studies for progression/response
- Immunotherapy tapering when stable; watch for relapses
Living with CIDP
- Track infusion dates, steroid doses, symptoms, side effects
- Plan rest around infusion cycles; hydrate well
- Maintain safe exercise routines (low-impact, supervised)
- Protect numb feet/hands from injury; inspect skin daily
- Seek workplace accommodations if mobility/sensation impaired
Complications
- Axonal loss leading to permanent weakness
- Steroid side effects (weight gain, osteoporosis, diabetes)
- IVIG reactions (headache, thrombosis, renal dysfunction)
- Falls, fractures due to neuropathy
Research & Future Directions
Research targets nodal/paranodal antibodies, B-cell modulation, complement inhibition, and biomarkers predicting relapse.
Experimental & Emerging Treatments
- FcRn Inhibitors (efgartigimod, rozanolixizumab): Lower pathogenic IgG levels with faster onset than IVIG.
- BTK Inhibitors: Under study to suppress B-cell signaling in autoantibody-positive CIDP.
- Gene Expression Profiling: Identifies subgroups for personalized therapy (immune nodopathies vs classic CIDP).
- Remyelination Agents: Experimental therapies aim to enhance Schwann cell repair post-inflammation.
Track CIDP with Diagnoza.care
Stay Ahead of Relapses – Log strength changes, infusion schedules, steroid tapers, rehab sessions, falls, pain levels, labs, and specialist visits; capture side effects; and let the AI companion highlight early signs of flare or treatment fatigue.
Medical Disclaimer: Informational only. Work with your neurologist/neuromuscular specialist for diagnostic confirmation, immunotherapy selection, and rehabilitation planning.
Sources: European Academy of Neurology, Peripheral Nerve Society, National Institute of Neurological Disorders and Stroke